| Symbol | SPTX |
|---|---|
| Name | SEAPORT THERAPEUTICS, INC. |
| Sector | UNDEFINED |
| Region | UNDEFINED |
| Industry | Pharmaceutical Preparations |
| Address | 6 TIDE STREET, BOSTON, MA 02110 |
| Telephone | 617-807-4062 |
| Fax | — |
| — | |
| Website | — |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0002042347 |
| Description | None |
Seaport Therapeutics to Present at Citi’s 2026 Biopharma Back to School Conference and Participate in 21st Annual Wells Fargo Healthcare Conference
Read moreNew Form SCHEDULE 13G - Seaport Therapeutics, Inc. <b>Filed:</b> 2026-08-14 <b>AccNo:</b> 0001193125-26-352401 <b>Size:</b> 126 KB
Read moreSeaport Therapeutics Reports Second Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Read moreHOMBACH ROBERT J. 🟢 acquired 13.0K shares of Seaport Therapeutics, Inc. (SPTX) at $18.14 Transaction Date: Jun 22, 2026 | Filing ID: 280175
Read more(90% Positive) SEAPORT THERAPEUTICS, INC. (SPTX) Announces Enrollment Update for participant Due to Patient Enrollment Issues, Regulatory Process, Safety Review, Efficacy Assessment
Read moreSeaport Therapeutics Reports First Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Read moreSeaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
Read moreNew Form SCHEDULE 13D - Seaport Therapeutics, Inc. <b>Filed:</b> 2026-05-11 <b>AccNo:</b> 0000950142-26-001350 <b>Size:</b> 126 KB
Read moreNew Form SCHEDULE 13G - Seaport Therapeutics, Inc. <b>Filed:</b> 2026-05-11 <b>AccNo:</b> 0000886982-26-000211 <b>Size:</b> 17 KB
Read more